Submission Guidelines

Article Types

Article Type	Max word count (first submission)	Figures and Tables	Max word count (after revision)	Electronic Supplementary Materials
Original Article	4,000	6 figures, 6 tables	5,000	Unlimited
Clinical Guideline**	4,000*	6 figures, 6 tables*	5,000	Unlimited
Systematic Review	6,000	10 figures, 10 tables	8,000	Unlimited
Editorial	2,000	2 figures OR 1 figure + 1 table		/
Letter to the Editor	1,000	1 figure		/

The word count includes only the main body of the text, namely: Introduction, Materials & Methods (if applicable), Results (if applicable), Discussion (if applicable).
Title, abstract, references, and legends do not count towards the maximum word limit.

*The editorial board may allow a higher word count and/or number of illustrative elements if deemed necessary/appropriate for a specific Guideline.
**Article type includes Consensus Statements, Position papers.

Manuscript Format

Initial Submission

The EANM Journal supports a format-free initial submission. Manuscripts will not initially be scrutinized for compliance with formatting requirements and style.

However, when submitting your manuscript, the following items must be present:
Title Page: must include title, author list, author affiliations, and contact details of corresponding author.
Main Text: must include Title, Abstract, Introduction, Materials & Methods (if applicable), Results (if applicable), Discussion (if applicable), and References.
Figures & Tables (as applicable): can be uploaded separately or in the main text at first submission. Maximum 6 panels.
Figure & Table Legends: can be uploaded separately or in the main text at first submission.
Disclosures:
Authors must include here the relevant statements about:

-Institutional Review Board approval
-Written informed consent
-Clinical trial registration (http://www.clinicaltrials.gov/).

For institutional board approval and informed consent, authors should use one of the following standard statements:
1."This study has been approved by the institutional review board [or equivalent body] (Number: xxxx). All subjects/patients/participants signed an informed consent form".
2."The study was approved by the institutional review board [or equivalent body] (Number: xxxx). The need for written informed consent was waived due to the nature of the study".
The prospective or retrospective nature of the study must be clearly stated.
Please refer to the provided "Disclosures Template" and see also sections "Ethical Standards" and "Materials and Methods".

Manuscript Sections

Title: must be clear, concise, and informative. It should include modality and disease, ideally also indicate study type (e.g., randomized clinical trial) and registry or clinical trial name.

Abstract (OA): maximum 300 words, structured into Background/Introduction, Methods, Results, Conclusion. For clinical trials, the name of the registry and the URL of trial registry record should be included at the end of the abstract.
Abstract (other article types): Maximum 300 words, not structured.

Introduction: should provide a brief overview of the field and background with enough references to explain why the study was performed. Ideally, the last sentence should detail the purpose of the study.

Materials and Methods: methods and procedures must be described in sufficient detail to allow reproducibility by others. The section should include and describe:

- Institutional Review Board and Informed Consent as appropriate
- The nature of the study (prospective, retrospective)
- Patient/participant selection
- Date ranges
- Sample selection and size derivation
- Checklist and flow diagram based on one of the following evidence-based statements as needed: STARD (http://www.stard-statement.org); CONSORT (http://www.consort-statement.org); PRISMA (http://www.prisma-statement.org/statement.htm); REMARK (http://www.nature.com/nrclinonc/journal/v2/n8/full/ncponc0252.html)

Adherence to the minimal reporting guidelines defined by https://www.equator-network.org/ is recommended.
Authors should apply the International Consensus Radiochemistry Nomenclature Guidelines and refer to recommendations published in "Consensus nomenclature rules for radiopharmaceutical chemistry — setting the record straight", Coenen and Gee et al., Nuclear Medicine and Biology at doi.org/10.1016/j.nucmedbio.2017.09.004.

Statistical methods should be provided in the last paragraph.

Results: should be presented in logical sequence in the text, along with tables and figures. The appropriate tables and figures should be referenced when summarizing the main observations. The statistical significance of the findings should be stated. Numerators and denominators should be provided for all percentages.

Discussion: should not contain a repetition of the results. The discussion should contain: 1. a summary of the rationale of the study and its main findings, 2. discussion of the main advances brought by the results and their implications related to other studies, 3. limitations and biases of the study, 4. conclusions and future perspectives/directions (as applicable).
Graphical Abstract: optional, pending evaluation.

References: There is no limit to the number of references allowed. Please also refer to **Similarity Checks and Self-citation** below for more details on self-citation policies.
The reference style is Vancouver system with numbers in text.
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.
List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.
Examples:
In text: "DPP9 negatively regulates the tyrosine kinase Syk [8]."
Reference to a journal publication:
[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun 2010;163:51–9.
Reference to a book:
[2] Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000.
Reference to a chapter in an edited book:
[3] Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors. Introduction to the electronic age. New York: EPublishing Inc; 2009, p. 281–304.
Additional notes:
Please use shortened form for last page number. e.g., 51–9.
For more than 6 authors, the first 6 should be listed followed by 'et al.' For further details you are referred to "Uniform Requirements for Manuscripts submitted to Biomedical Journals" (J Am Med Assoc 1997;277:927–34), see also http://www.nlm.nih.gov/bsd/uniform_requirements.html

Ethical standards

For studies involving human participants, Institutional Review Board approval and written informed consent (as needed) should be provided. Authors must also declare that their study adheres to the ethical standards described in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
For studies involving animals, Institutional Review Board approval should be provided. Authors should also provide information on the ethical treatment of their animals.

Editorial Policies

Similarity Checks and Self-citation

Submitted manuscripts undergo similarity check via iThenticate software. Manuscripts containing substantial text similarity to other sources (including other sources from the same author group) will be returned to the authors or receive immediate rejection, depending on the severity of the text overlaps.

The EANM Journal closely scrutinizes manuscripts for self-citation, which must be kept to under 15%. Manuscripts where self-citation exceeds 15% will be rejected before peer-review.

Authorship

The EANM Journal follows the guidelines and recommendations on authorship established by the International Committee of Medical Journal Editors (ICMJE) on the role of Authors and Contributors. *The EANM Journal* allows up to 2 corresponding authors. A request for more than 2 corresponding authors must be justified.

We encourage corresponding authors to register to ORCID (Open Researcher and Contributor ID) before online submission. ORCID is a persistent digital identifier that allows unique identification of individuals and lists their unique contributions to research, review activity, authorship, and more. For more information, and to register, please visit ORCID.org.

Use of Large Language Models (LLMs) and Artificial Intelligence (AI) tools

Large Language Models (LLMs), such as ChatGPT, cannot be considered authors. The use of an LLM or AI-tool for AI-assisted copyediting (improving readability of the text, checking grammar, spelling, and punctuation) should be declared at submission.

The use of Generative AI images is not permitted.

The use of Generative AI tools for evaluation of manuscripts from peer-reviewers is also not permitted, as this is considered a violation of confidentiality.

Algorithm and Code Transparency/Availability

The *EANM Journal* requires authors to provide sufficient details in the Materials and Methods section to allow replication of the study.

Authors are required to deposit in a publicly accessible repository any computer code or binary executable algorithm used in the study that supports central claims in the paper.

Details about the code or binary executable algorithm (or any restrictions thereof) should be provided in a dedicated "Code Availability" section in the Materials and Methods.

If the data utilized in the study cannot be shared, at least anonymized example samples shall be shared in order to allow evaluation of the code or binary executable algorithm on them.

Sufficient documentation regarding any development environment or third-party libraries necessary to set up and run the methods, including their versions and their access or download links, shall be provided.

Code or binaries can be deposited in dedicated storage providers (not affiliated to EANM), for example:

GitHub: https://github.com

Bitbucket: www.bitbucket.org/

SourceForge: sourceforge.net/

Or DOI-minting repositories (not affiliated to EANM), such as:
Zenodo: https://zenodo.org/
CodeOcean: https://codeocean.com/

Submission to Preprint Server

Submission to a preprint server is allowed by *The EANM Journal*. Authors should explicitly declare the preprint posting in the declarations section, including DOI and licensing terms, upon submission of the manuscript. The authors have the responsibility to update the preprint in due course with the DOI and URL of the published article.

Fast-track review

Authors can request the Editor to consider fast-track review if their manuscript is particularly time sensitive. To do so, please contact the Editorial office at eanm.journal@eanm.org explaining the reasons for the request.

Fast-track clinical submission

Authors of a manuscript that fits the Aims and Scope of *The EANM Journal* and received a rejection from *NEJM*, *The Lancet Oncology*, *European Urology*, the *Journal of Clinical Oncology*, *Alzheimer's and Dementia*, or *Nature Medicine* are encouraged to request a **fast-track clinical submission** to expedite the peer-review and publication of their manuscript. Authors should contact the Editorial Office at eanm.journal@eanm.org requesting a fast-track clinical submission including the following documents:

- Brief description of the impact of the manuscript in nuclear medicine and allied sciences
- Previous reviewer reports and decision letter
- Manuscript with tracked changes
- Rebuttal letter with point-by-point response to the previous reviewers and editors' requests.

The Editorial Board will take the previous reviews and decision into account and will provide a decision, following fast-track review, within 7 days.